# A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients

> **NCT00190671** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 103 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pemetrexed
- **DRUG:** cyclophosphamide
- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00190671
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2009-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190671, "A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00190671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*